HARMONY BIOSCIENCES HOLDINGS, INC. Cash and Restricted Cash
HARMONY BIOSCIENCES HOLDINGS, INC. (HRMY) had Cash and Restricted Cash of $550.04 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-04
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $550.04M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $589.67M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $752.77M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $647.27M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $550.04M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $589.67M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $752.77M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $647.27M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $546.32M 10-Q · filed 2026-08-04 |
| 2025-03-31 | $489.27M 10-Q · filed 2026-05-07 |
| 2024-12-31 | $453.27M 10-Q · filed 2026-08-04 |
| 2024-09-30 | $387.64M 10-Q · filed 2025-11-04 |
| 2024-06-30 | $317.57M 10-Q · filed 2025-08-05 |
| 2024-03-31 | $333.25M 10-Q · filed 2025-05-06 |
| 2023-12-31 | $311.93M 10-K · filed 2026-02-24 |
| 2023-09-30 | $324.85M 10-Q · filed 2024-10-29 |
| 2023-06-30 | $317.67M 10-Q · filed 2024-08-06 |
| 2023-03-31 | $288.71M 10-Q · filed 2024-04-30 |
| 2022-12-31 | $244.53M 10-K · filed 2026-02-24 |
| 2022-09-30 | $262.09M 10-Q · filed 2023-10-31 |
| 2022-06-30 | $237.28M 10-Q · filed 2023-08-01 |
| 2022-03-31 | $225.25M 10-Q · filed 2023-05-02 |
| 2021-12-31 | $235.06M 10-K · filed 2025-02-25 |
| 2021-09-30 | $190.45M 10-Q · filed 2022-11-01 |
| 2021-06-30 | $160.44M 10-Q · filed 2022-08-02 |
| 2021-03-31 | $141.92M 10-Q · filed 2022-05-03 |
| 2020-12-31 | $229.38M 10-K · filed 2024-02-22 |
| 2020-09-30 | $222.49M 10-Q · filed 2021-11-09 |
| 2020-06-30 | $77.03M 10-Q · filed 2021-08-10 |
| 2020-03-31 | $72.27M 10-Q · filed 2021-05-11 |
| 2019-12-31 | $25.21M 10-K · filed 2023-02-21 |
| 2019-09-30 | $102.02M 10-Q · filed 2020-11-12 |
| 2018-12-31 | $84.02M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |